Navigation Links
TapImmune to Participate in Two Upcoming Investor and Industry Conferences
Date:3/22/2017

JACKSONVILLE, Fla., March 22, 2017 /PRNewswire/ -- TapImmune, Inc. (NASDAQ: TPIV), a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics for the treatment of cancer and metastatic disease, today announced that it will participate in two upcoming Investor and Industry conferences.

Dr. Glynn Wilson, Chairman and CEO of TapImmune, will provide an overview of the company's business, clinical pipeline and partnering opportunities for its proprietary PolyStart technology platform during his presentation at the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, NY.  Additionally, Dr. Wilson will serve as a panelist during the conference's "Cancer Vaccines: Immuno-Priming and Tumor Antigens" panel discussion.

Continue Reading
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.
TapImmune to Participate in the 5th Annual Cancer Biopartnering & Investment Forum hosted by Sachs Associates in New York, and the Oligonucleotide & Peptide Therapeutics Conference in Boston.

Concurrently, Dr. John Bonfiglio, President and Chief Operating Officer of TapImmune, will provide an overview of the company's unique approach during a presentation titled "Synthesis, Purification and Formulation of a New T Cell Vaccine Using 5 Novel Proteins," during the S2 Oligonucleotide & Peptide Therapeutics Boston Conference in Boston, MA.

Event:Sachs' 5th Annual Cancer Biopartnering & Investment ForumDate: Tuesday, March 28, 2017Times: Company presentation: 10:35 am (Eastern Time)

Cancer vaccine panel discussion: 2:00 pm (Eastern Time)Location:The New York Academy of Sciences, New York, NY Event:S2 Oligonucleotide & Peptide Therapeutics Boston Conference Date: Wednesday, March 29, 2017Time: 1:30 pm (Eastern Time)Location:Royal Sonesta Boston, Cambridge, MA

The presentation of the Sachs' 5th Annual Cancer Biopartnering & Investment Forum will be webcast live and will remain available as an archive following the presentation.  To access the webcast, please visit the events page section of the TapImmune website at http://tapimmune.com/events/.

About TapImmune, Inc.
TapImmune, Inc. is a leader in the immunotherapy of woman's cancers advancing multiple Phase 2 and Phase 1b/2 clinical studies for the treatment of ovarian and breast cancer. The company's peptide or nucleic acid-based immunotherapeutics, comprise one or multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T-cells, helper T-cells and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. The company's technologies may be used as stand-alone medications or in combination with current treatment modalities.

Please visit the company's website at www.tapimmune.com for more details. 

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the risks set forth in the company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The company assumes no obligation to update the forward-looking statements.

 

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/tapimmune-to-participate-in-two-upcoming-investor-and-industry-conferences-300427763.html


'/>"/>
SOURCE TapImmune, Inc.
Copyright©2017 PR Newswire.
All rights reserved


Related medicine technology :

1. TapImmune Launches Phase 2 Ovarian Cancer Trial In Platinum-Sensitive Patients
2. TapImmune: Year End 2016 Update
3. TapImmune Announces Finalization of License Agreement With Mayo Clinic to Commercialize a HER2neu Vaccine
4. TapImmune to Present at the LD Micro Invitational in Los Angeles on June 7, 2016
5. TapImmune to Present at the 3rd Annual Growth Capital Expo in Las Vegas on May 4, 2016
6. TapImmune Announces Phase 2 Ovarian Cancer Trial Study with AstraZeneca/MedImmune and Sloan Kettering Cancer Institute
7. TapImmune Completes GMP Manufacturing and Release of TPIV 200 Vaccine
8. TapImmune Granted Fast Track Designation by U.S. Food & Drug Administration for its Lead Vaccine TPIV 200 in the Treatment of Ovarian Cancer
9. TapImmune to Present at Biotech Showcase 2016 in San Francisco on January 11, 2016
10. Immuno-Oncology Company, TapImmune Inc., Moves Corporate Headquarters to Jacksonville Florida
11. TapImmune to Present at Aegis Capital 2015 Growth Conference in Las Vegas on October 9, 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/14/2017)... 2017 The Bio Supply Management Alliance (BSMA) ... Fremont and the Biomedical Manufacturing Network to ... California by providing a platform ... fostering workforce development. The primary focus of this alliance ... as well as small and mid-sized biomedical companies. ...
(Date:6/13/2017)... June 13, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that the U.S. Food and Drug Administration (FDA) has ... 2015 relating to its Zhejiang, China ... "The successful clearance of the Warning Letter related ... facility is a measure of the progress we have made ...
(Date:6/11/2017)... 2017  Eli Lilly and Company (NYSE: LLY ... studies of galcanezumab, an investigational treatment for the prevention ... several key secondary endpoints for galcanezumab compared to placebo ... (EVOLVE-1, EVOLVE-2 and REGAIN) will be presented today at ... Boston . "The ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... June 26, 2017 , ... ... leakage is revolutionizing the way women look and feel about themselves and their ... of female sexual dysfunction and urinary leakage head on with a ground breaking ...
(Date:6/26/2017)... (PRWEB) , ... June 26, 2017 , ... KICKICO ... a whitepaper that pledges to solve many catastrophic issues within funding campaigns. KICKICO ... , The typical notion of crowdfunding - the raising of funds through the power ...
(Date:6/25/2017)... , ... June 24, 2017 , ... Create a feel-good lyric music video in Final ... and sound in the timeline and write in the lyrics to any song. ProLyric flies ... out. Each line of the text can be added modularly for optimal control. ProLyric makes ...
(Date:6/25/2017)... ... 2017 , ... CareSet Labs released the Root NPI Graph today at the ... greatly improved version of the Doctor Referral teaming dataset commonly available from Medicare. , ... called the the “Doctor Referral Dataset” as released by Medicare and “DocGraph” as released ...
(Date:6/24/2017)... Tampa, Fla. (PRWEB) , ... June 24, 2017 ... ... Fla., is now offering genetic testing for medications in select Florida and Texas ... of pharmacogenomics. , This new application of genetic testing recognizes the role ...
Breaking Medicine News(10 mins):